AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
Subscribe To Our Newsletter & Stay Updated